Baseline clinical characteristics
| Reproducibility cohort | Disease progression cohort | ||||
| Echocardiography | CT | All | Echocardiography follow-up | Calcium score follow-up | |
| Number | 18 | 15 | 81 | 71 | 51 |
| Age (years) | 70±8 | 73±7 | 72±8 | 72±8.2 | 73±7 |
| Male | 12 (67) | 10 (67) | 55 (69) | 50 (70) | 34 (67) |
| Body mass index (kg/m2) | 30±4 | 30±6 | 29±5 | 28±4 | 28±4 |
| Systolic blood pressure (mm Hg) | 152±20 | 151±18 | 146±20 | 144±18 | 143±17 |
| Comorbidity | |||||
| Diabetes mellitus | 4 (22) | 4 (27) | 15 (18) | 13 (18) | 9 (18) |
| Hypertension | 13 (72) | 11 (73) | 60 (74) | 50 (70) | 36 (70) |
| Documented CAD | 9 (50) | 6 (40) | 33 (41) | 31 (44) | 26 (51) |
| Current smoker | 8 (44) | 6 (40) | 9 (11) | 8 (11) | 5 (9) |
| Serum creatinine (mg/dL) | 0.89±0.23 | 0.70±0.11 | 1.01±0.31 | 1.00±0.30 | 0.98±0.28 |
| Medications | |||||
| ACE inhibitors | 8 (44) | 6 (40) | 32 (40) | 27 (38) | 20 (39) |
| AIIRB | 4 (22) | 3 (20) | 11 (13) | 9 (13) | 7 (13) |
| Beta-blockers | 7 (39) | 7 (47) | 33 (41) | 30 (43) | 23 (45) |
| Statins | 14 (78) | 9 (60) | 54 (66) | 46 (64) | 34 (67) |
| Baseline echocardiographic assessment | |||||
| AV jet velocity (m/s) | 3.5 (3.2–4.0) | 3.3 (3.0–3.8) | 3.4 (2.8–4.1) | 3.3 (2.7–3.9) | 3.0 (2.5–3.6) |
| AV mean gradient (mm Hg) | 25 (21–31) | 24 (22–30) | 25 (16–36) | 24 (14–32) | 21 (13–25) |
| AV area (cm2) | 1.1 (0.8–1.3) | 1.1 (1.0–1.3) | 1.1 (0.9–1.4) | 1.2 (0.9–1.5) | 1.2 (1.0–1.5) |
| Dimensionless index | 0.30 (0.23–0.37) | 0.32 (0.25–0.40) | 0.32 (0.25–0.39) | 0.33 (0.26–0.39) | 0.36 (0.30–0.40) |
| CT assessment | |||||
| AV calcium score (AU) | 989 (497–1708) | 1178 (579–2109) | 1339 (553–2422) | 1190 (505–2182) | 874 (459–1792) |
Mean±SD, median (IQR) and number (percentage).
AIIRB, angiotensin 2 receptor antagonists; AS, aortic stenosis; AU, Agatson Units; AVA, aortic valve area; CAD, coronary artery disease; LV, left ventricle; LVH, left ventricular hypertrophy.